Influence of rosuvastain on the lipid profile and inflammatory markers in patients with gout and arterial hypertension

Zolotariova N. A., Romanchenko M. I. Influence of rosuvastain on the lipid profile and inflammatory markers in patients with gout and arterial hypertension. Journal of Education, Health and Sport. 2017;7(9):627-635. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.1133228 http://ojs.ukw.edu.pl/index.php/johs/article/view/5167 The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 1223 (26.01.2017). 1223 Journal of Education, Health and Sport eISSN 2391-8306 7 © The Authors 2017; This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 15.08.2017. Revised: 20.09.2017. Accepted: 29.09.2017. INFLUENCE OF ROSUVASTAIN ON THE LIPID PROFILE AND INFLAMMATORY MARKERS IN PATIENTS WITH GOUT AND ARTERIAL HYPERTENSION N. A. Zolotariova, M. I. Romanchenko Odessa National Medical University, Odessa, Ukraine Abstract Currently there is scarce data on lipid-lowering effects of rosuvastatin in rheumatologic pathology, moreover there are no current studies of its anti-inflammatory activity in patients with gout comorbid with arterial hypertension (AH). The purpose of this study is to investigate the lipid-lowering and anti-inflammatory effect of combination therapy with the addition of rosuvastatin in patients with gout AH. We measured and compared the level of total cholesterol, TG, LDL, VLDL, HDL, atherogenic index (AI) as well as biochemical parameters of inflammation (ESR, C-reactive protein, sialic acids, seromucoid and fibrinogen-A in 30 patients (29 male, 1 female) with gout + AH, the observation period was 43 ± 9 days. The study showed decrease in total cholesterol by 29,2% to 3,88 ± 0,78 mmol/L (p<0,0001), decrease in triglycerides by 23,91% to 1,40 [1,12 – 1,94] mmol/L (p=0,01), LDL decrease by 36,95% to 1,86 ± 0,51 mmol/L (p<0,0001), normalizing in 86,67% of patients, no effect on HDL, remaining at a level of 1,23 mmol/L and significant normalization of atherigenic index decreasing to 2,23 ± 0,83 (-30,53%, p<0,0001). Inflammation markers showed significant positive dynamics: ESR significantly decreased to 15,90 ± 9,33 mm/h (p